CRISPR/Cas9-Based Gene Editing for Correcting Inherited Channelopathies

Area of Science:

• Cardiovascular Genetics
• Molecular Medicine
• Gene Editing Technologies

Background:

• Inherited cardiac channelopathies cause significant morbidity and mortality, particularly in young individuals.
• Current treatments manage symptoms but do not correct the underlying genetic defects.
• There is a critical need for curative therapies targeting the genetic basis of these conditions.

Purpose of the Study:

• To review the current state of CRISPR-based genome editing strategies for inherited cardiac channelopathies.
• To highlight the potential of gene editing to provide durable, disease-modifying therapies.
• To discuss the challenges and future innovations in translating these technologies to the clinic.

Main Methods:

• Review of recent advances in CRISPR/Cas9, base editing, and prime editing technologies.
• Analysis of preclinical studies using animal models and patient-derived cells.
• Examination of novel viral and nonviral delivery systems for gene editing components.

Main Results:

• Gene editing has shown potential in preclinical models to correct pathogenic variants causing channelopathies.
• Studies demonstrate restoration of electrophysiologic stability and suppression of arrhythmias.
• Durable functional benefits have been observed in proof-of-concept studies.

Conclusions:

• CRISPR gene editing presents a promising avenue for treating inherited cardiac channelopathies by directly repairing genetic defects.
• Significant translational challenges, including off-target effects, delivery, and immunogenicity, require further innovation.
• Continued advancements in gene editing and delivery technologies are crucial for clinical translation and preventing sudden cardiac death.